Technical Analysis for LCTX - Lineage Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
D 2.57 -2.28% -0.06
LCTX closed up 3.54 percent on Wednesday, July 28, 2021, on 32 percent of normal volume.
Earnings due: Aug 4
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical LCTX trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction -2.28%
Lower Bollinger Band Touch Weakness -2.28%
Below Lower BB Weakness 1.18%
Down 3 Days in a Row Weakness 1.18%
Down 4 Days in a Row Weakness 1.18%
Lower Bollinger Band Touch Weakness 1.18%
50 DMA Resistance Bearish -2.65%
NR7 Range Contraction -2.65%
NR7-2 Range Contraction -2.65%
Down 3 Days in a Row Weakness -2.65%
Older End-of-Day Signals for LCTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 2 hours ago
60 Minute Opening Range Breakdown about 4 hours ago
10 DMA Resistance about 7 hours ago
Up 1% about 7 hours ago
Rose Above Previous Day's High about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Lineage Cell Therapeutics, Inc. Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Clinical Development Immunotherapy Bone Cancer Immunotherapy Stem Cells Non Small Cell Lung Cancer Small Cell Lung Cancer Macular Degeneration Drug Delivery Cell Therapy Related Macular Degeneration Degenerative Disease Osteoarthritis Degenerative Diseases Retina Injuries Human Disease Aesthetics Spinal Cord Pivotal Progenitor Cell Starch Bone Grafting Dendritic Cell Helium EMV Stem Cell Therapy Biotime Dry Age Related Macular Degeneration Treatment Of Degenerative Diseases

Is LCTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.13
52 Week Low 0.8012
Average Volume 1,406,880
200-Day Moving Average 2.21
50-Day Moving Average 2.70
20-Day Moving Average 2.71
10-Day Moving Average 2.65
Average True Range 0.13
ADX 17.88
+DI 12.41
-DI 23.06
Chandelier Exit (Long, 3 ATRs) 2.59
Chandelier Exit (Short, 3 ATRs) 2.85
Upper Bollinger Bands 2.87
Lower Bollinger Band 2.55
Percent B (%b) 0.24
BandWidth 11.78
MACD Line -0.03
MACD Signal Line -0.02
MACD Histogram -0.0168
Fundamentals Value
Market Cap 394.48 Million
Num Shares 150 Million
EPS 0.23
Price-to-Earnings (P/E) Ratio 11.34
Price-to-Sales 85.10
Price-to-Book 2.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.78
Resistance 3 (R3) 2.76 2.70 2.76
Resistance 2 (R2) 2.70 2.66 2.71 2.75
Resistance 1 (R1) 2.66 2.63 2.68 2.68 2.74
Pivot Point 2.60 2.60 2.61 2.61 2.60
Support 1 (S1) 2.56 2.56 2.58 2.58 2.52
Support 2 (S2) 2.50 2.53 2.51 2.51
Support 3 (S3) 2.46 2.50 2.51
Support 4 (S4) 2.48